News | July 20, 2022
GSK’s Haleon begins trading in LSE
Completion of the demerger of Haleon and share consolidation of GSK
Completion of the demerger of Haleon and share consolidation of GSK
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
100% efficacy against severe Covid-19 disease and hospitalizations
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)